Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R G Fenton

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 1998
Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cellsT J Sayers, A D Brooks, J K Lee, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 10, 2001
Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2)J W Park, M E Gruys, K McCormick, et al.
Cancer Research|July 15, 1995
CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patientsH Qin, W Chen, M Takahashi, et al.
The Online Journal of Current Clinical Trials|July 1, 1992
Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II StudyM Sznol, R G Steis, J W Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1993
Dose-related immunologic effects of levamisole in patients with cancerJ Janik, W C Kopp, J W Smith, et al.
Journal of the National Cancer Institute|January 18, 1995
A phase I clinical trial of flavone-8-acetic acid in combination with interleukin 2J T Holmund, W C Kopp, R H Wiltrout, et al.
Journal of the National Cancer Institute|June 17, 1992
Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinomaM Sznol, J W Clark, J W Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2B D Curti, D L Longo, A C Ochoa, et al.
The New England Journal of Medicine|March 18, 1993
The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatinJ W Smith, D L Longo, W G Alvord, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992
The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignanciesJ W Smith, W J Urba, B D Curti, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 1998
Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cellsT J Sayers, A D Brooks, J K Lee, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 10, 2001
Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2)J W Park, M E Gruys, K McCormick, et al.
Cancer Research|July 15, 1995
CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patientsH Qin, W Chen, M Takahashi, et al.
The Online Journal of Current Clinical Trials|July 1, 1992
Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II StudyM Sznol, R G Steis, J W Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1993
Dose-related immunologic effects of levamisole in patients with cancerJ Janik, W C Kopp, J W Smith, et al.
Journal of the National Cancer Institute|January 18, 1995
A phase I clinical trial of flavone-8-acetic acid in combination with interleukin 2J T Holmund, W C Kopp, R H Wiltrout, et al.
Journal of the National Cancer Institute|June 17, 1992
Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinomaM Sznol, J W Clark, J W Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2B D Curti, D L Longo, A C Ochoa, et al.
The New England Journal of Medicine|March 18, 1993
The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatinJ W Smith, D L Longo, W G Alvord, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992
The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignanciesJ W Smith, W J Urba, B D Curti, et al.
Pageof 5